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Objectives: This paper presents a simulation model for evaluating the possible effects of a screening and vaccination
campaign against Human Papillomavirus [HPV] in Kenya.
Method: A System Dynamics model was developed using the iThink™ computer simulation package. The model was
based on data extracted from epidemiological, demographic and published research and where data was not
available, expert opinion was sought. The deterministic model stratified the population by vaccination status,
screening status and HPV infection status. The model was simulated to estimate outputs for the next 50 years
from 2011. Cost Utility indicators of Disability Adjusted Life Years (DALYs) and cost per averted DALY were used
for economic evaluation.
Results: The model predicted that catch up vaccination had the greatest impact in reducing the prevalence of
cervical cancer. This was followed by Primary vaccination, with early detection through Screening having the
lowest impact of the three choices of interventions in respect of averted cases of cervical cancer and DALY estimates.
Conclusion: Kenya as a country should consider adoption of secondary /catch up vaccination as an immediate
measure to curb cervical cancer followed by primary vaccination of pre-adolescent girls. Screening should be a
complementary measure(s). This model provides a policy decision support vehicle that can allow for choice between
different interventions based on their expected outcomes. It also allows modification to accommodate new research
results and information to assess the clinical impact of different policies and interventions in cervical cancer
management in Kenya.
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Burden of cervical cancer in Kenya
Cervical cancer is estimated to account for 15% of all fe-
male cancers and cause approximately 46,000 deaths each
year in women aged 15–49 in developing countries [1,2].
Cervical cancer continues to have a devastating effect on
women’s health in Kenya. It is the most frequent cancer
among women in Kenya. It is also the second most fre-
quent cancer among women between 15 and 44 years of
age after breast cancer [3]. Specific disease indicators are
summarized in Table 1.
A crude incidence rate of 16.5 per 100,000 population
per year was reported in Kenya in 2009. Estimates indicate
that every year 2600 women are diagnosed with cervical* Correspondence: lukibitok@uonbi.ac.ke
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article, unless otherwise stated.cancer in Kenya and 2100 die from the disease. It is pro-
jected that in 2025, there will be 4100 new cases of cer-
vical cancer in Kenya and 3300 deaths as a result of
cervical cancer. Some facilities in the capital city, Nairobi,
have reported as high as 10 – 15 new cases of cervical
cancer each week [3].Strategies employed in management of cervical cancer in
Kenya
Different stakeholders have taken different measures to
curb cervical cancer in Kenya. These interventions range
from inclusion of cervical cancer in training curricula, pre-
vention and promotion services such as screening, vaccin-
ation, male circumcision as well as health education.
Treatment interventions have also been undertaken. For
those with positive tests, provision of curative services
which include Cryotherapy, loop electrosurgical excisiontral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 PARAMETER[S] estimates and sources
Factor[s] Value Source of
information
Notes
Cervical cancer BASE CASE [Year 2010]
Prevalence rate 38.8 [1]
Crude Incidence rate/100000 16.5 [1] Year 2009
Number of deaths 2100 [1]
Number of cases 4178 [1]
No diagnosed with cervical cancer each year 2635 [1]
2011 life expectancy in Kenya 60.7
Average age of onset of cervical cancer 45 Years Baseline survey
Average duration of cervical cancer 7.5years Experts opinion
DALY assumptions for cancer
Age of onset of death or disability in years [a] 40. Baseline survey
Disability weight [D] 0.81
Percent of surviving cases with sequelae 0% Expert opinion Assumed all eventually
will die from Ca Cervix
Mortality to incidence ratio .55 [1]
Mortality from other causes not directly connected to Cancer of Cervix 0.008 Experts opinion This was considered
insignificant hence
not modeled.
Crude mortality rate 13.2 [2]
Age-standardized mortality rate 23.4 [2]
Screening coverage rate within 3 years 3.2 [2]
Rate of primary vaccination 0.01 Experts opinion Limited data available
Rate of secondary vaccination 0.03 Experts opinion Limited data available
No of primary vaccinations required to avert one case of Ca cervix 250 [3] Assuming a life time
protection
No of primary vaccinations required to avert one case of Ca cervix 600 [3] Assuming waning off
of vaccine protection
after 10 years.




Percentage with access to internet 7.5 Baseline survey
Percentage with access to mobile phone 96 Baseline survey
Percentage with positive attitude towards use of e-health 95 Baseline survey
PROGNOSIS OF undiagnosed Ca. cervix
Percentage of death from invasive cancer 33 [4]
time span between infection of HPV and development
of carcinoma in Situ
7 to 15 years [5]
Years taken by precancerous cells to progress to cancerous cells 5 [5]
Percentage of progress from precancerous stage to undiagnosed stage one 3 – 10% [5] [4]
Percentage of regression from precancerous stage to ‘clean’ state
through immune reaction
90-97% [4-6]
Progression of undiagnosed cancer from stage 2 to Stage 3 40% [6]
Progression of Undiagnosed cancer from stage 3 to stage 4 80% [6]
PROGNOSIS OF diagnosed Ca. cervix
Treatment impact/five year survival rate
Early intervention survival rate 92% [6] .277
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Table 1 PARAMETER[S] estimates and sources (Continued)
Stage 1 survival rate 90% [6] .271
Stage 2 survival rate 60-80% [6] Average 70% used
in this model
.211
Stage 3 survival rate 50% [6] .151
Stage 4 survival rate Less than 30% [6] 30% used in this
model .091
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ent levels of health institutions may be provided [4].
Currently the Kenyan government has a mix of policies,
advocating for Abstinence [A], Be faithful [B] and the use
of Visual Inspection with Acetic Acid (VIA) and Visual In-
spection with Lugol’sIodine (VILLI) as screening methods
in low resource settings. VIA and VILLI have been
underutilized considering their low costs and simplicity
of use - However VIA also has very low specificity as
the cervix reacts to many other conditions including
non cancerous changes, polyps and other infections
[4,5]. Treatment interventions are expensive and may
not be sustainable in a low resource setting [4].
In general, Cancer control in Kenya is an integrated
evidence-based activity consisting of primary prevention,
early detection, treatment and rehabilitation. However
each of the interventions has its own benefits and
challenges.
Vaccination
Primary vaccination against HPV infections has demon-
strated high efficacy, immunogenicity and safety [6].
Since HPV is sexually transmitted, pre-exposure vaccin-
ation may be administered to both young boys and girls.
However, vaccination of boys has been found to be less
cost effective in a low resource setting [7] and is debat-
able in countries with adequate resource settings [8]. For
the vaccine to be effective there must be high coverage
of vaccination among pre adolescent girls and lowering
of vaccine costs [6]. Research has also demonstrated that
catch up vaccination usually performed among older
women is effective as a preventive strategy [9]. Not all
women qualify for catch up vaccination which is recom-
mended for women between 10 to 45 years. Women
who are already infected with HPV would also not bene-
fit from vaccination [9]. HPV has over 100 sub-types;
there is no single vaccine which can provide immunity
against all these strains. This is compounded further by
a report that even in developed economies around 15%
-30% of women do not complete the vaccination doses
[10,11].
Two main vaccines are currently available in Kenya.
Gardasil which costs on average $150 [Kshs 12,000] and
targets HPV types 6, 11, 16 & 18, with some cross-protection against emerging and related HPVs 45 and 31
[12], is reported to have an effectiveness rate of 98% and
the effect lasts for 4 years. Gardasil has been recom-
mended for 9 to 26 year olds and is given in three di-
vided doses over a period of 6 months. Cervarix which
costs $300-$360 [approximately Kshs20,000] [12] and
among HPV vaccines has been reported as the most ex-
pensive in the world of vaccination. Cervarix’s effect
lasts for six years on average and targets HPV types 16
and 18. It is reported to be 92% to 100% effective with a
wider age coverage of 10–45 years [13]. Even though
these vaccines may not provide lifelong immunity and
booster doses are required after 10 years, the probability
of an immunized woman having HPV infection is low-
ered substantially and with this effect potentially lasting
over a decade, even a single complete dose of vaccin-
ation is beneficial [13]. Despite the challenge of the high
cost of vaccination and many women lacking the know-
ledge of cervical cancer and HPV vaccine, Kenyan women
have been reported to have a positive attitude towards
HPV vaccination [14].
Challenges faced in cervical cancer screening
Kenya, like other developing countries, faces a number
of challenges in cervical cancer screening. The high costs
associated with screening as well as a lack of information
on screening, poor access to organized preventive screen-
ing services, ineffective infrastructure characterized by few
existing facilities that are under-resourced, over-burdened
and lack adequate equipment and staff [15]. The long dis-
tance between facilities and clients’ residences increases
the transport costs, clients’ time costs and the cost of
sending Pap smear samples to and from the processing la-
boratories. These factors reduce the number of clients
who return for test results. Chirenje et al. [15] however
argue thathealth care institutions in East and Central
Africa have the necessary infrastructure for cervical cancer
screening, but these facilities experience frequent short-
ages of materials needed for taking Pap smears. Ineffective
follow-up results in poor quality data. A large number of
women in Kenya lack consumer information on cervical
cancer, and preventive measures including screening.
Women do not receive accurate information about the ac-
tual cost of services [16] andabout 15% of the few women
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[17].
A lack of updated cancer registries with incomplete
risk factor data curtails reliable population based esti-
mates for incidence rates, mortality rates and effective-
ness of interventions [17].
Faced with all these challenges, it is important that the
country adopts a coherent policy as well as alternative
effective intervention strategies on cervical cancer man-
agement in Kenya.
Screening in Kenya
It is estimated that only 1-2% of women in Kenya have
been screened for cervical cancer in the last five years
and that only 3.2% of all women aged between 18 and
69 years are screened every 3 years [3]. Other case stud-
ies and projects have reported an estimated coverage of
between 1% to 10% [18]. A number of projects on
screening for cervical cancer in both urban and rural
settings have been conducted. Some provided screening
alone with referral of suspected cervical cancer cases to
health care facilities, while others offered ‘on site’ imme-
diate treatment. The effectiveness of referral to poorly
equipped health care facilities with a delayed treatment
period of almost six months raises the question of whether
it is ethical to perform mass screening without accessing
appropriate treatment services and follow up [19].
Even though there are a number of screening methods
available, not all methods can be deployed in developing
countries due to limited resources. The type of screening
chosen by the specific country depends on a number of
factors, including availability of resources, infrastructure,
health-seeking behaviours, the frequency of screening
and the nature of the screening test [9]. For developing
countries to have effective cervical cancer screening, sys-
tematic screening coupled with treatment options must
be available. These screening interventions must be inte-
grated into the existing health systems and should be
economically, socially and culturally acceptable. Cost is a
major factor in considering a cervical cancer screening
strategy. Goldie et al. [20] estimated the total discounted
cost of screening utilizing VIA at $15; the use of HPV
DNA testing which required two visits was estimated at
$18 while cytological examination was estimated at $25.
It is to be noted that the low specificity of some screen-
ing methods results in false positive results which may
result in unnecessary treatment and increased anxiety
among women.
Treatment strategies
Treatment of cervical cancer is dependent on the stage
of infection. Treatment methods include cryotherapy,
Loop Electrosurgical Excision Procedure [LEEP], Cone
biopsy and Laser ablation [21]. These methods areeffective as long as the cervical cancer has not spread to
beyond the local level. Once metastasis has commenced
then other interventions must be considered. These in-
clude surgery, chemotherapy, radiation or a combination
of any of the interventions. Treatment intervention of
cervical cancer has been estimated to reduce mortality
rate by 76% [15]. Different stages of HPV infections have
different treatment costs. Goldie et al [20] estimated the
cost of treatment of invasive cancer stage one at 1,552,
stage two at 1,925 while distant stage which included
stage 3 and 4 at 1,995 in 2000 international dollars.
Why system dynamics?
In order to overcome the above mentioned challenges of
real world experiments and future uncertainties, we
need to perform in silico experiments to design and test
policies that cover a range of possible futures. One
method that can be used is Health Systems Simulation
[HSS]. HSS is the application of computer simulation to
explore, understand and improve the interaction be-
tween structure and action in health care and policy as
well as model the complexities of modern health ser-
vices. Computer simulation has been viewed as a mature
and powerful tool for modelling the health system to test
how different factors may improve efficiency, effective-
ness and equity in situations where it is not possible to
conduct real-world experiments [22].
System Dynamic Simulation becomes a reliable way to
test a hypothesis, evaluate the likely effect on policies
and provide a possible answer to most myopic real life
experiments. This method has been applied widely in
the health care sector. Royson et al. [23], used System
Dynamics to develop policies and programs in England
while Fett MJ [24] used Powersims System Dynamics
modelling software to model two Swedish county trials
of mammographic screening and the trade-offs between
participation and screening intervals [23,24]. The practice
of in silico experiments and the systematic application
of systems engineering approaches have been viewed as
more cost-effective and have been encouraged in rede-
signing and improving performance of health care sys-
tems [23].
Previous cervical cancer management models
Different models have been used to evaluate cervical
cancer management. Sanders and Taira [25] used decision
maker software to develop a Markov model in evaluation
of effectiveness and cost effectiveness of prophylactic HPV
vaccine. Abbot et al. [26], used agent based simulation to
demonstrate how cells acquire cancer while Goldhaber-
Fiebert et al [27] modelled HPV for analysis of screening
and vaccination in the United States and found that while
screening reduced the life time risk of cervical cancer by
76%, vaccination reduced the same by 75% while a
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et al. [28] used mathematical models that demonstrated
reduction of cervical cancer through both vaccination
and screening.
Even though the above models have been developed
and utilized in various scenarios, no benchmark exists
against which a model can be evaluated in determining
either the best fit of parameters or representation of dis-
ease process [29]. At the same time few if any models
have focused on Kenya as a developing country. This
study is therefore aimed at developing a SD model for
evaluating the possible effect of primary vaccination, sec-
ondary vaccination and screening campaigns specifically
for Kenya in the area of Cervical Cancer Management.
Methods
A system dynamics model was developed using iThink™-
version 9.1.3 software package (http://www.iseesystems.
com/softwares/Version913Features.aspx). Detailed model
version is available as Additional file 1.
System Dynamics is a system of differential equations
solved using integral calculus approximations:
Stock tð Þ ¼
Z t
t0ð Þ
inflow−outflowð Þ  dt þ Stock t0ð Þ ð1Þ
Where t represents the stock, t0 represents initial value
of stock; dt is a time step which represents the rate of
change with respect to time.
The model is an open, dynamic, deterministic, lumped
compartmental model consisting of stocks and flows,
with information feedbacks. Data was derived from pre-
vious published literature, cancer registries and where
data was not available an expert opinion was sought.
This methodology is in line with documented method-
ologies [30]. Table 1 provides the details and source of
data used to estimate model parameters.
The choice of model and software took into consider-
ation the availability of data, availability of software,
background skills of the researchers, structure of cervical
cancer, the management processes and the objectives of
the study.
Overview of the model structure, features and its use
A snapshot of the model population structure is shown
in Figure 1. Figure 2 shows the model’s general and fe-
male population outputs. Figure 3 (showing the vaccin-
ation sector) and Figure 4 (showing the screening and
treatment intervention sector) further elaborate the
structure of the model.
Boxes represent population stock; clouds represent
births and deaths, single arrows represent flows from
one stock to the next while single circles with linkingsmaller arrows represent causative/influencing factors
(connectors and auxiliary variables). The model com-
prises a female population of aging chain of girls and
women with or without HPV infection. The female
population was grouped into given age groups; The fe-
males were divided into seven age groups: [0–5], [4-9],
[10-14], [15-24], [25-44], [45–64] and over 65 years based
on age groups of published data on cervical cancer [3].
The population is stratified by mutually exclusive health
states characterized by vaccinated or non-vaccinated sta-
tus, HPV infection status, stage of cancer and screened or
non-screened, detected or undetected cancer. The model
starts with the number of infant girls [age less than 1 year]
born in Kenya in the year 2010 [3]. This population is as-
sumed to grow at the birth rate of 3.2%. These girls ma-
ture to be pre-adolescent girls aged 9 years. The model
assumes vaccination of pre-adolescent girls at the age of
9 years and before turning 10 years. This is because by age
9, the conversion of dormant columnar epithelium of the
endo-Cervical canal into squamous epithelium has not yet
occurred hence the cells are still not susceptible to HPV
infection [31,32]. This is in line with the minimum rec-
ommended age of 9 to 12 years for pre-exposure vac-
cination by the Centre for Disease Control [CDC] [33]
and others [34].
It is also assumed that at this age the girls are not yet
sexually active. The efficacy of the vaccine was assumed
to be lifelong hence the lifetime immunity against HPV
once vaccinated. The rate of Primary vaccination is a
factor of accessibility and the attitude of caregivers to-
wards the primary vaccination. The [5-9] nine years age
group is stratified into the primary vaccinated and non-
primary vaccinated. The population of girls who received
primary vaccination permanently exit the model.
The model then follows up on the girls who did not
receive primary vaccination. It is assumed that all the
non primary vaccinated girls are exposed to HPV infec-
tion. As the girls progress through the aging chain, they
are eligible for catch up or secondary vaccination be-
tween the ages of [10-44] years. The rate of secondary
vaccination is assumed to be a function of accessibility,
knowledge and attitude towards catch-up vaccination.
Those receiving secondary vaccination permanently exit
the model, assuming lifelong efficacy of the vaccine.
The model further assumes;
i. That all the females seeking vaccination will
complete the full dose of vaccine.
ii. That 38.8% of all the never vaccinated females will
acquire HPV infection based on the prevalence of
HPV in Kenya.
iii. That only the females who missed both primary and
secondary vaccination are eligible for screening
against HPV.
Figure 1 General population sector.
Kivuti-Bitok et al. Cost Effectiveness and Resource Allocation 2014, 12:26 Page 6 of 19
http://www.resource-allocation.com/content/12/1/26iv. That only a proportion of the women who missed
both primary and secondary vaccination will
undergo cervical cancer screening later in life while
others will miss this vital intervention.
v. That all the HPV infections among the screened
women will be detected and subjected to
appropriate treatment.
vi. That HPV infection among the unscreened women
will progress naturally except these women will not
benefit from treatment.
vii. That a small proportion of the population of
women with unscreened /undiagnosed cervical
cancer may have ‘accidental’ opportunity for
screening in the course of their seeking health services.
viii.That depending on the stage of this ‘accidental’
screening and diagnosis, they move to the group of
screened and diagnosed population and subsequently
benefit from treatment interventions.
The model then follows up on the prognosis of the



















Figure 2 Trends of general and female population.Cervical Cancer. This group of women exits the model
permanently through death.
The main input variables are primary vaccination, sec-
ondary vaccination and screening rates. The potential
impact of these interventions on reduction of cervical
cancer cases was studied. The main output variables
were: the number of women receiving primary and sec-
ondary vaccination, the number of women screened
against HPV, averted cases of cervical cancer and mor-
tality rates from cervical cancer. Disability adjusted life
years (DALYs) were used to estimate the burden of dis-
ease. DALYs are used as an indicator of burden of a par-
ticular condition. DALYs are calculated by adding the
total sum of years lived with disability caused by the
condition otherwise referred to as Years of Life lived
with disability (YLD) and years of life lost (YLL) due to
early death as a consequence of the disease condition.
These YLL values are based on the present value of life
expectancy with a social discount rate. DALYs adjust-
ment is based on the severity and duration of illness.
One DALY is equivalent to loss of one year which would09:06    04 Sep 2014
GENERAL AND FEMALE POPULATION
2037.50 2050.75 2064.00
Years





Figure 3 Snap shot of vaccination sector.
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are an indicator of both years of life and functional loss
and hence the aim of interventions is to reduce the
DALYs. DALYS are a recommended measure of health
benefits in developing countries [35]. Other indicators of
impact for this model include incidence rates of cancer,
expected rise in cancer cases, averted cases of invasive
cancer and DALYs estimates. The effects of different inter-
ventions were then studied and compared. Synergy be-
tween two or more alternative strategies was evaluated.
Validation and verification of the SD Model
The model was validated through animation, face validity,
predictive validation and extreme condition tests [36]. The
demographic sector of the model was first validated
through checking if it could produce close estimates of
referenced demographic characteristics elsewhere (http://
esa.un.org/wpp/unpp/p2k0data.asp). Error of EstimationFigure 4 Snap shot of screening and treatment sector.of 30% was deemed an acceptable level. The error of esti-
mate may be attributed to imperfect calibration and un-
accounted for environmental interferences. Calibration is
aimed at minimizing the error of parameter estimates [37].
Sensitivity analysis
Sensitivity analysis assessed the effect of parameter varia-
tions on model results. The level of screening, primary
and secondary vaccinations was varied from 0.001 to 1.0.
A slider input device was provided in the interface of the
model. For accurate integration of equations, the fourth
order RungeKutta and a DT (Step Size) of 0.25 were
applied.
Model simulation
Simulations were then run with different levels of pa-
rameters. The population dynamics in relation to cancer
are simulated over a period of 50 years (2010–2060). It
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follows a birth cohort to estimated life expectancy. These
experiments attempt to demonstrate the current land-
scape of Cervical Cancer prevention and control strategies
in Kenya as well as simulate possible future landscapes. A
number of ‘what if ‘scenarios were simulated.
The prognosis of cervical cancer with and without treat-
ment is as indicated in Table 1. It is assumed that once
the disease has progressed to stage 3, treatment options
are geared towards improving quality of life and palliative
care rather than elimination of the infection [19].
The simulated results of different proposed interven-
tions are presented. The policy experiments include;
1. Business as usual (base-case) scenario.
2. Varying the levels of primary vaccination.
3. Varying the levels of catch up/secondary vaccination.
4. Varying the levels of screening.
5. Combining and varying screening and vaccination
levels.
Even though the model can perform different levels of
experiment values, for the purposes of this paper, the
WHO-CHOICE standard geographical coverage of 50%,
80% and 95% of eligible cases receiving intervention are
utilized. A ‘realistic’ scenario of 30% coverage was also
simulated based on a study done by Royston et al. who
used 30% as realistic coverage of health intervention in
France [38]. The results were compared against a base-
case scenario.
Structure of cervical cancer management model
Figure 1 shows the population growth dynamics with a
birthrate of 3.2%, the trends of total female population
in comparison to the general population. The simulation
results were compared with projections of the Kenyan
population by the United Nations on (http://esa.un.org/
unpd/wpp/unpp/p2k0data.asp). The results as well as
the respective error of estimations are shown in Table 2.
The error of estimate can be attributed to the changing
birthrate over time due to family planning practice, in-
creasing levels of education, urbanization and economic
empowerment [39]. The model however utilized a con-
stant birth rate.
Results
The Model was run using iThink™ software and the results
were presented in the form of graphs/figures. Figure 5
shows simulated Annual trends of diagnosed, undiag-
nosed, new cases, total cases of cervical cancer and total
deaths due to cancer. This is taken as the base case sce-
nario, using age standardized incidence rates per 100,000
Population. The average screening rate of 3.2% was used.
The rate of primary and secondary vaccinations could notbe established and expert opinion estimated coverage at
0.1% and 0.3% respectively and the rate of screening was
taken at 3.2% [3]. A birth rate of 3.2 and an average life ex-
pectancy rate of 60.9 years were utilized in the simulation.
These trends closely mirror other projections which esti-
mated the annual death rate among cervical cancer clients
at 65%, and estimated 2,454 new cases and 1676 deaths
each year [40].
Figure 6 shows trends of new cases of cervical cancer
at status quo. The women aged 55 to 64 years have the
largest number of new cases of cervical cancer. This age
group also has the highest level of age specific incidence
rate estimated at 105/100,000 women [3].
Figure 7 shows the trends of undiagnosed cervical can-
cer among women who missed primary vaccination, sec-
ondary vaccinations and screening. Undiagnosed stage 1
has the highest number of undiagnosed patients. This
may be attributed to the slower rate of disease progres-
sion from stage one to stage two. Undiagnosed Stage 4
has the least number of clients among the undiagnosed
group; this may be attributed to the fast rate of progres-
sion from stage 3 to stage 4 as well as the high death
rate (Approximately 65%) of clients at this stage as the
clients rarely benefit from Medical Intervention.
Figure 8. Shows trends of cases of diagnosed cervical
cancer.
For diagnosed cervical cancer patients, the majority
are in stage one. This may be attributed to the treatment
impact at this stage with probability of regression and
Cure. Diagnosed stage 4 has more clients compared to
the undiagnosed stage 4. This may be attributed to early
intervention at stage one and two among the diagnosed
group as well as delayed death at stage four of diagnosed
patients due to treatment interventions. The treatment
interventions delay progression from one stage to the
next.Output indicators
Cost utility analysis was used as indicated by changes in
Disability Adjusted Life Years [DALYs] and Total Cost of
averted DALYs. DALYs consisted of Years of Life Lost
(YLL) and Years of Life Lived with Disability (YLD).
The cost per averted DALY was based on a simplified
calculation based on the total cost of intervention divided
by the DALYs averted.
DALYs = YLD + YLL. Fox-Rushby and Hanson [35] cal-
culation method was adopted Table 3.Impact of different interventions on DALY trends
Combined interventions
The model sought to estimate the impact of combined
intervention strategies on the trends of DALYs and
averted DALYs









2010 0-4 3345 3045 −9.0%
2015 0-4 3584 2635 −26.5%
2020 0-4 3792 2959 −22.0%
2025 0-4 4024 3322 −17.4%
2030 0-4 4315 3720 −13.8%
2035 0-4 4606 4156 −9.8%
2040 0-4 4849 4634 −4.4%
2045 0-4 5029 5162 2.7%
2050 0-4 5183 5747 10.9%
2055 0-4 5290 6396 20.9%
2060 0-4 5396 7117 31.9%
2010 5-9 2887 2859 −1.0%
2015 5-9 3276 3238 −1.2%
2020 5-9 3525 3222 −8.6%
2025 5-9 3742 3472 −7.2%
2030 5-9 3981 3845 −3.4%
2035 5-9 4277 4288 0.3%
2040 5-9 4573 4787 4.7%
2045 5-9 4821 5339 10.8%
2050 5-9 5004 5949 18.9%
2055 5-9 5159 6625 28.4%
2060 5-9 5266 7374 40.0%
2010 10-14 2421 2421 0.0%
2015 10-14 2855 2880 0.9%
2020 10-14 3250 3063 −5.8%
2025 10-14 3505 3224 −8.0%
2030 10-14 3724 3488 −6.3%
2035 10-14 3965 3847 −3.0%
2040 10-14 4263 4278 0.3%
2045 10-14 4560 4768 4.6%
2050 10-14 4809 5314 10.5%
2055 10-14 4992 5921 18.6%
2060 10-14 5148 6593 28.1%
2010 15-24 4204 4204 0.0%
2015 15-24 4509 4607 2.2%
2020 15-24 5192 5108 −1.6%
2025 15-24 6026 5523 −8.4%
2030 15-24 6684 5938 −11.2%
2035 15-24 7163 6435 −10.2%
2040 15-24 7628 7045 −7.6%
2045 15-24 8171 7773 −4.9%
2050 15-24 8770 8618 −1.7%
2055 15-24 9316 9577 2.8%
Table 2 Female population trends by age groups
(Continued)
2060 15-24 9750 10653 9.3%
2010 25-44 5041 4929 −2.2%
2015 25-44 6129 5726 −6.6%
2020 25-44 7057 6551 −7.2%
2025 25-44 7911 7387 −6.6%
2030 25-44 8879 8209 −7.5%
2035 25-44 10018 9040 −9.8%
2040 25-44 11348 9923 −12.6%
2045 25-44 12663 10898 −13.9%
2050 25-44 13802 11994 −13.1%
2055 25-44 14850 13236 −10.9%
2060 25-44 15936 14639 −8.1%
2010 45-64 2013 2013 0.0%
2015 45-64 2376 2747 15.6%
2020 45-64 2822 3497 23.9%
2025 45-64 3471 4264 22.8%
2030 45-64 4349 5044 16.0%
2035 45-64 5352 5833 9.0%
2040 45-64 6228 6636 6.5%
2045 45-64 7070 7465 5.6%
2050 45-64 8033 8338 3.8%
2055 45-64 9167 9275 1.2%
2060 45-64 10479 10297 −1.7%
2010 65+ 580 580 0.0%
2015 65+ 703 751 6.8%
2020 65+ 895 979 9.4%
2025 65+ 1121 1239 10.6%
2030 65+ 1356 1520 12.1%
2035 65+ 1617 1814 12.2%
2040 65+ 1987 2118 6.6%
2045 65+ 2540 2432 −4.2%
2050 65+ 3283 2760 −15.9%
2055 65+ 4119 3108 −24.5%
2060 65+ 4888 3483 −28.7%
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ii. 30% (realistic Coverage) of Primary Vaccination,
Secondary Vaccination and screening.
iii. 50% Coverage of Primary Vaccination, Secondary
Vaccination and screening.
iv. 80% Coverage of Primary Vaccination, Secondary
Vaccination and screening.
v. 95% Primary Vaccination, Secondary Vaccination
and screening.
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Figure 5 Trends of, undiagnosed cases (1) diagnosed cases (2), total cases of cervical cancer (3), new cases (4) and total deaths
from cervical cancer (5).
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Figure 6 Trends of new cases at base case scenario.
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Figure 7 Trends of cases of undiagnosed cervical cancer at base case scenario.
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Figure 8 Trends of cases of diagnosed cervical cancer at base case scenario.
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Table 3 Illustrates the variables of Fox-Rushby and
Hanson [35] calculation method
YLD
[K] Age weighting modulation factor 1
[W] is a constant 0.1658
[y] Discount rate expressed as decimals 0.03
[Alpha] Age at diagnosis of cervical cancer 45
[Beta] Parameter for age weighting function 0.04
[l] Average duration of disability 15
[D] Disability Index of cervical cancer 0.81
YLL
[alpha 2] Age of death 60.7
[life2] Standard expectation of life at age of
diagnosis with cervical cancer
15.7
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DALYs averted at Base Case Scenario. In the year 2060,
only 94,676 DALYs would be averted at the current state
of intervention in management of cervical cancer. At a
realistic coverage of 30% of the three interventions,
4,454,100 DALYs will be averted, while 5,269,002would
be averted at 50% coverage levels with 80% and 95%
coverage levels accounting for 5,891,677 and 6,088,880
respectively (Figure 10). This would then mean that even
a realistic coverage of the three interventions would be a
significant target in management of Cervical Cancer in
Kenya.
Figure 9, shows a general reduction in DALYs with in-
crease in coverage rates a reflection of the impact of the















Figure 9 Trends of DALYs at base case scenario, at 30%, 50%. 80%Impact of primary vaccinations
The model sought to estimate the impact of primary
vaccination. In this model, Primary vaccination refers to
vaccination at 9 years of age only. Other models have set
primary vaccination from age 9 to age 12 [33,41,42]. It
has been reported that 250 vaccinations among girls less
that 12 years are required to avert one case of cervical
cancer assuming immunity of a life span and 600 with
waning immunity after 10 years [25].The impact of different rates of primary vaccination
coverage
Figure 11 show predicted levels of DALYs averted in dif-
ferent levels of coverage of primary vaccination coverage.
The DALYs averted increase with increase of coverage of
primary vaccination.Impact of secondary vaccination
The impact of Secondary Vaccination on DALYs averted
was simulated. It was noted that 324 Secondary vaccina-
tions are required to avert one case of cervical cancer
among eligible women [43]. This is a 29.6% increase in
the number of vaccinations requiredin comparison with
primary vaccination and hence an increase in cost of
vaccination. For the purposes of this model, Secondary
Vaccination has been defined to cover the women aged
10 to 44 years. Other studies have set the age bracket at
different figures thirty three [41,42].
Figure 12, shows simulated trends of DALYs averted at













and 95% coverage rates of the three interventions.
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Figure 10 Averted DALYS at base case (1), 30% coverage (2), 50% coverage (3), 80% coverage (4) and 95% coverage (5).
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Figure 11 Impact of primary vaccination on DALYs averted at base case (1), 30% (2), 50% (3), 80% (4), 95% (5) coverage levels.
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Figure 12 Impact of secondary vaccination on DALYs averted at base case (1), 30% (2), 50% (3), 80% (4) and 95% (5) coverage levels.
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Figure 13 Impact of different levels of screening coverage on DALYs averted.
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Figure 14 Cost per averted DALY at base case (1) and at 30% coverage of the primary vaccination, secondary vaccination and
screening interventions.
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earlier in time in comparison to the impact of primary
vaccination. The results in Figure 11 and Figure 12 dem-
onstrated that catch up vaccination would be a more ef-
fective short term approach in the prevention of HPV
infections as compared to primary vaccination. Over the
simulated 50 year period, secondary vaccination would
result in aversion of 52% to 56% more DALYs in com-
parison to primary vaccination. These figures however
can change depending on the set age limits of both pri-
mary and secondary vaccination.
Impact of screening
Screening intervention has been identified as an effective
preventive measure as long as it is done systematically,
covering a large proportion and is done concurrently
with treatment. Apart from resources needed, effective-
ness of screening is also affected by such factors as the
number of tests required, the sensitivity and specificity
of screening methods available as well as the recom-
mended screening intervals [44]. This model assumes ef-
fective cervical cancer screening coverage.
It is assumed that the proportion of girls who were
not vaccinated are at risk of HPV infection. This is the
group which is subjected to HPV screening and that all
the women who have been confirmed to have HPV aresubjected to appropriate treatment options. The base
case rate of 0.1% of primary and 0.3% secondary vaccin-
ation remains.
Screening coverage was shown to reduce DALYs. . The
rate of change however reduced after a 50% coverage rate
as noted from Figure 13. However at a realistic coverage
(30% of all the interventions) screening contributed to less
averted DALYs in comparison to primary and secondary
vaccination. Screening would contribute 85% to 89% less
DALYs than secondary vaccination and 68% to 75% less
averted DALYS than primary vaccination. The impact of
screening is expected to be realized later in comparison
with primary vaccination and catch up vaccination.
Generally the simulation results demonstrate that, an
increase in the level of coverage of the different inter-
ventions, resulted into an increase in the reduction of
DALYs as well as an increase in DALYs averted.
Figure 14 compares the cost of averting each DALY at
base case and at a realistic coverage of the three inter-
ventions. The cost per DALY averted decreases signifi-
cantly with increases in intervention coverage.
By the Year 2060, and at a realistic coverage, secondary
vaccination would account for the largest portion of
averted cases (at 98%) followed by primary vaccination
(1.2%) while screening would contributed the lowest with
less than 1%.
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This model assessed the possible impact of primary vac-
cination, secondary vaccination and screening campaigns
in the management of cervical cancer in Kenya. Current
levels of coverage were compared with different inter-
vention scenarios including a ‘realistic’ coverage of 30%
of the three interventions. The model confirmed effect-
iveness of the three strategies in management of cervical
cancer; however the possible impact of the interventions
varied according to the various scenarios simulated.
Secondary vaccination against HPV was found to have
the highest impact of the three choices of intervention.
Different studies have emphasized the potential impact
of vaccination as an intervention in reduction of HPV
infection and cervical cancer mortality [21]. Secondary
vaccination would account for a reduction of over 50%
incidence rates. This is consistent with Baussano et al.
[45] who simulated a 50% reduction in HPV prevalence
after the introduction of catch up vaccination. It is noted
that even with higher primary vaccination coverage, the
impact of vaccination is realized only after 10–15 years.
This is consistent with findings of Franco and Cuzick
[13]. After rolling out an extensive HPV vaccination a
recent study in Australia reported a reduction ranging
from 0.1 to 0.38% in both low grade and high grade abnor-
malities in a period of 3 years [46]. Five years later the
AustralianNational HPV vaccine programs reported suc-
cess in reduction of not only HPV cervical cancer related
lesions but also a reduction of 9.65% in genital warts [47].
Primary Vaccination can only achieve its potential im-
pact if it reaches all vulnerable groups. Nationwide School
based vaccination programs may go along way in meeting
this need [13] The trade off in vaccination intervention
must be considered in relation to age specific incidences,
vaccination coverage rate, efficacy of the vaccine and risk
of viral re-infection among others [46,48]. A challenge of
resistance to vaccination due to low acceptability among
respondents is possible. This has been reported in France
withthe uptake of hepatitis vaccine [38] as well as HPV
vaccination uptake in USA where less than 50% of teenage
girls completed the three doses of HPV vaccine. The rea-
sons associated with resistance included some parents of
teenagers feeling that the vaccine was not needed, safety
concerns and fear of increase in sexual activity, conveni-
ence of completion of the vaccine and lack of factual in-
formation on the vaccine [49]. It is important to note that
women in Kenya and Botswana have been reported to
have high levels of acceptability of HPV vaccines
[14,50]. This is a strength in these country which could
be used as a basis for HPV vaccine. Low income coun-
tries have been documented to have a more supportive
environment and the school based HPV vaccination
programs model has been documented to result in a
high coverage rate [51].Primary vaccination must take into account economic
considerations. It has been argued that an HPV vaccin-
ation exercise may not be economically viable in devel-
oping economies due to the high cost of vaccination,
the un-sustainability of such an economic endeavor by
GAVI as well as other more competing health priorities
[52,53]. However HPV vaccine may be the most effect-
ive measure in the future [54,55].
Screening was shown to have the lowest impact of the
three choices of intervention in terms of the number of
cervical cancer cases averted and the impact on reduc-
tion of DALYs. However it is important to note that the
primary purpose of screening is early diagnosis and
treatment and not necessarily a preventive measure. Cer-
vical cancer screening has been considered as an effect-
ive method of reduction in cervical cancer mortality,
accounting for a 70% reduction in mortality rate in de-
veloped countries and contradicting results in develop-
ing countries [17]. The Nordic and some European
countries have succeeded in a reduction of cervical can-
cer where systematic screening was done. However cer-
vical cancer screening has been reported to have a low
rate of success attributed to a number of factors which
include low test sensitivity of HPV testing, uneven ac-
cess to screening and coverage, lack of follow up in
women with abnormal results, poor treatment and
poor quality of care among others [13]. It has been sug-
gested that in a low resource setting, women of over
30 years should have at least one screening done. How-
ever this test has a 30%-50% probability of false nega-
tive results [18].
The simulated results of this model concur with the
theory that screening may have minimal effect in control
of cervical cancer with coverage of less than 50%. The
results support Goldie et al. [48], who reported that
coverage of over 50% of HPV screening resulted in min-
imal change to the cervical cancer rate. Denny et al. [17]
suggested that for successful Cervical Cancer screening
in a low resource setting to take place, a number of es-
sential requirements must be met. These include but are
not limited to low cost, low screening technology, diag-
nosis and treatment offered on site, wide coverage of the
majority of at risk women, appropriate educational pro-
grams for both clients and health care workers as well as
a built in mechanism for evaluation of screening pro-
grams. It is important to not only have massive screen-
ing but also have surveillance programs with recall and
follow up embedded in existing health services [18]. It
has been argued that it is unethical to provide screening
services in the absence of a treatment option [19].
Screening has also been found to be less acceptable with
some women describing it as ‘invasive’ to their privacy
and being against the cultural expectations [56]. These
factors pose a challenge to screening as an intervention.
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screening interventions should not be ignored.
Limitations of the study
The model did not make a distinction between regularly
screened and occasionally screened women. Efficacy of
vaccine was assumed to be life-long, however vaccine ef-
fects last for a limited period of time, usually around
10 years, and hence a booster is required later. If efficacy
of the vaccine is poor, then there is poor impact on re-
duction of cervical cancer. The need for a vaccination
booster was not included in the model. The impact of
male circumcision and vaccination of Boys against HPV
were also not modelled. HPV has been known to cause
other genital cancers. The effects of HPV vaccination on
these other cancers were not simulated and hence it
may be necessary to develop a model which incorporates
the impact on all these other cancers.
There is limited cervical cancer epidemiological data
available in Kenya. Therefore this population based model
relied mostly on aggregate point data which did not allow
for probability variations. Even though population based
models are easier to construct, they may miss out on the
uniqueness of individual clients and hence may not allow
the history of each individual client to be tracked. The
model was not differentiated by socioeconomic status
hence socioeconomic status interventions could not be
established.
All three interventions occur in a dynamic context af-
fected by Information Communication and Technology
(ICT) among others. The model was limited in its ability
to include all other possible confounding variables. How-
ever the model allows for modification to accommodate
for new research findings.
Recommendations
As a matter of policy, Kenya should consider secondary
vaccination and primary vaccination as a matter of prior-
ity. Screening should be complementary to primary and
secondary vaccination. This is based on the assumption
that the country could afford all options. With the pro-
posed financial support of HPV vaccine by GAVI, the ex-
pected cost will be between $5 and $15 which is close to
the average cost of screening. There is a need to develop
a model on the implication of vaccination in developing
economies, and Africa in particular.
Conclusion
This model generated reasonable estimates in the evalu-
ation of the effects of different interventions on cervical
cancer management in Kenya. Interim cervical cancer
management policy has been derived. The model charts
informed debate leading to development of new consen-
sus policy on screening and vaccination. Cervical cancerneeds to be managed and monitored continuously with
screening being implemented as a complimentary inter-
vention to vaccination. Kenya as a country needs to con-
sider implementing catch up and primary vaccination as
an urgent measure to curb cervical cancer.
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